Santen and TRACON Pharmaceuticals announced the companies will discontinue the development of DE-122 for the treatment of wet age-related macular degeneration (wAMD) following the review…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.